Chemotherapy-related peripheral neuropathy
Conditions
Interventions
Electroacupuncture Group:Acupoints: Hegu, Quchi, Zusanli, Taichong, Baxie, Bafeng. Procedure: Insert needles perpendicularly or obliquely until de qi is achieved, then connect to electroacupuncture de
Sham Acupuncture Group:Acupoints: Non-acupoints. Procedure: Superficial insertion (approximately 2-3 mm) at non-acupoints, connect to electroacupuncture device but no current output. Retain needles fo
Sponsors
General Hospital of Ningxia Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. 18 years old <= age <= 80 years old; 2. Diagnosed with cancer, using platinum-based or taxane-based drugs, with an expected lifespan of more than 1 year; 3. Willing to accept electroacupuncture treatment; 4. No history of peripheral neuropathy, and no symptoms or signs of peripheral nerve damage after chemotherapy; 5. Normal intelligence, able to complete the assessment scales.
Exclusion criteria
Exclusion criteria: 1. Those in the acute phase of mental illness, or unable to cooperate with acupuncture treatment, or those with a fear of acupuncture; 2. Patients with severe infections, extreme physical weakness, or in the acute phase of severe heart, lung, or brain diseases; 3. Individuals currently participating in other clinical studies; 4. Pregnant women; 5. Those who have used any of the following medications within the past week: Duloxetine, Pregabalin, Amitriptyline, Gabapentin, Oxycodone with Acetaminophen, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Analgin, Paracetamol, Lidocaine patches, Capsaicin patches, Monosialotetrahexosylganglioside, or Reduced Glutathione; 6. Individuals with severe bleeding disorders or coagulation dysfunction, such as hemophilia, thrombocytopenic purpura, or long-term use of anticoagulants (e.g., Warfarin), where acupuncture may lead to uncontrollable bleeding or hematoma; 7. Those with local skin infections or damage at the acupuncture site, such as boils, ulcers, burns, or herpes; 8. Individuals with tumor lesions at the acupuncture site; 9. Those with symptoms or signs of peripheral nerve damage before chemotherapy, such as numbness or weakness in both hands and feet, or the absence of tendon reflexes in all four limbs; 10. Individuals with uncontrolled high blood pressure (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg in a resting state); 11. Patients with implanted cardiac pacemakers; 12. Those who have received acupuncture treatment within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CIPN Remission Rate at Week 8 (Proportion of Patients with NRS Score Decreased by =30% from Baseline); | — |
Secondary
| Measure | Time frame |
|---|---|
| CIPN20 Scale;Numerical Rating Scale (NRS) Score;NCI-CTCAE Grading;Quality of Life Scale (FACT-G/EORTC QLQ-C30);Electromyography (EMG);Magnetic Resonance Neuroimaging;Neurosonography;Safety Outcomes (Including Needle-Related Adverse Events such as Infection, Hematoma, Syncope, Other Adverse Events, and Serious Adverse Events [SAEs]); | — |
Countries
China
Contacts
Public ContactWang Zhenhai
General Hospital of Ningxia Medical University
Outcome results
None listed